The US Food and Drug Administration (FDA) is planning to allow Americans to get a different booster shot of a COVID-19 vaccine than the one initially taken, Reuters news agency reported on Tuesday, citing the New York Times (NYT).
In September 2021, the FDA had authorised a booster dose of Pfizer Inc (NYSE:PFE) and partner BioNTech's (Nasdaq:BNTX) two-shot COVID-19 vaccine for those aged 65 and older and some high-risk Americans.
The FDA's advisory panel had also backed the use of Moderna Inc (Nasdaq:MRNA) and Johnson & Johnson's (NYSE:JNJ) COVID-19 vaccine booster shots.
According to Monday's NYT report, the US government would not recommend one shot over another and it might note that using the same vaccine as a booster when possible is preferable.
A study by the US National Institutes of Health last week showed people who got Johnson & Johnson's COVID-19 vaccine as a first shot had a stronger immune response when boosted with vaccines from Pfizer and Moderna, Reuters noted.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial